An ingredient used in pediatric patients to treat 5 (IL-5) intermediate diseases. This ingredient helps to treat some diseases in this population, including asthma, mild asthma, moderate asthma, severe asthma, mild eye asthma, moderate eye asthma, severe eye asthma, uncontrolled eupolyphenyl asthma, eupolyphenyl asthma, sub regional asthma, chronic obstructive pulmonary disease, Polio, hypertension, sinusitis, poliomyelitis, poliomyelitis, poliomyelitis, poliomyelitis, cerebral dermatitisA pediatric patient weighing less than 40 kg had moderate dermatitis and severe atomic dermatitis； Its components include an antibody, which contains the heavy chain amino acid sequence shown in SEQ ID 1 and the light chain amino acid sequence shown in SEQ ID 2, as well as the number of effective treatments for the antibody.Through subcutaneous management of pediatric targets, the maximum plasma concentration of antibody (c.8344a.739) was about 101960 ± 03345 mg / ml, and the area value under the curve was about 454.39 ± 158876 mg / ml.Una composición para tratar enfermedades mediadas por interleucina 5 (IL-5) en sujetos pediátricos. La composición es útil para tratar una enfermedad seleccionada del grupo que consiste en asma, asma leve, asma moderada, asma grave, asma eosinofílica leve, asma eosinofílica moderada, asma eosinofílica grave, asma eosinofílica no controlada, asma eosinofílica, asma subeosinofílica, enfermedad pulmonar obstructiva crónica enfermedad, granulomatosis eosinofílica con poliangeítis, síndrome hipereosinofílico, poliposis nasal, penfigoide bulloso, esofagitis eosinofílica, dermatitis atópica, dermatitis atópica moderada y dermatitis atópica grave en un paciente pediátrico que pesa menos de 40 kg； en donde dicha composición comprende un anticuerpo que contiene la secuencia de aminoácidos de cadena pesada mostrada en SEQ ID Nº 1 y la secuencia de aminoácidos de cadena ligera mostrada en SEQ ID Nº 2 y una cantidad terapéuticamente eficaz del anticuerpo administr
